% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Ambrozkiewicz:307635,
      author       = {F. Ambrozkiewicz and E. Ali and M. Bradova and P. Slavík
                      and P. Martinek and M. Svaton and A. Hemminki and K.
                      Hemminki$^*$},
      title        = {{M}utational landscape of lung adenocarcinoma in
                      {C}zechia.},
      journal      = {Cancer treatment and research communications},
      volume       = {46},
      issn         = {2468-2942},
      address      = {Amsterdam},
      publisher    = {Elsevier},
      reportid     = {DKFZ-2026-00106},
      pages        = {101095},
      year         = {2026},
      note         = {#LA:C020#LA:Z999#},
      abstract     = {Limited DNA sequencing data on lung cancer (LC) patients
                      are available from Eastern Europe where male smoking is
                      commonest in Europe. As sequence analysis is the
                      prerequisite for targeted therapy we provide such data from
                      Czechia (CZ). Additionally, we present novel sequencing data
                      for adenocarcinoma subtypes. Panel sequencing data on 1218
                      adenocarcinoma patients were available from a single
                      histology laboratory for 2016 to 2024. The highest variant
                      frequencies were observed for KRAS $(51.6\%),$ EGFR
                      $(18.8\%)$ and TP53 $(16.3\%).$ Commonest types of variants
                      were codon 12 mutations for KRAS, exon 21 L858R for EGFR and
                      V600E BRAF. EGFR variants were more common in females
                      $(25.3\%$ vs $11.5\%).$ KRAS mutations were frequent in
                      males $(56.9\%$ vs $46.9\%),$ as were PIK3CA mutations
                      $(3.8\%$ vs $1.9\%).$ KRAS mutations were frequent in
                      patients diagnosed below 70 years, whereas EGFR, PIK3CA and
                      MET alterations were frequent in patients above age 70
                      years. As stage distinctions, high prevalence of KRAS
                      mutations was found in early stage tumors (II and IIIA) and
                      of TP53 mutations in stages IIIB and IV. As to
                      adenocarcinoma subtypes, lepidic type showed a high
                      frequency of EGFR variants. We could show differential
                      distribution of gene variants by sex, diagnostic age, stage
                      and subtype of adenocarcinoma. The data are in line with
                      current literature that targeted treatment is being applied
                      for selected LC patients in CZ. It can be expected that LC
                      patients benefit from therapeutic and other clinical
                      improvements, which however do not reduce the primary
                      importance of anti-smoking campaigns.},
      keywords     = {Age of onset (Other) / Mutation type (Other) / Panel
                      sequencing (Other) / Stage (Other) / Subtype of
                      adenocarcinoma (Other)},
      cin          = {C020 / Z999},
      ddc          = {610},
      cid          = {I:(DE-He78)C020-20160331 / I:(DE-He78)Z999-20160331},
      pnm          = {313 - Krebsrisikofaktoren und Prävention (POF4-313)},
      pid          = {G:(DE-HGF)POF4-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:41529505},
      doi          = {10.1016/j.ctarc.2026.101095},
      url          = {https://inrepo02.dkfz.de/record/307635},
}